Tyra Biosciences, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. at the 2026-05-28 meeting.
“2. The ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The appointment was ratified by the votes indicated: For Against Abstain Broker Non-Votes 53,092,820 1,316 3,246 –”
Shareholder Votes
Tyra Biosciences, Inc. shareholders approved Election of three Class II directors to serve for a three-year term expiring at the 2029 Annual Meeting of Stockholders. at the 2026-05-28 meeting.
“1. The election of three directors to serve as Class II directors for a three-year term to expire at the 2029 Annual Meeting of Stockholders. The following three Class II directors were elected by the votes indicated: For Withheld Broker Non-Votes Habib J. Dable 44,242,803 476,602 8,377,977 Susan Moran, M.D., M.S.C.E. 44,529,688 189,717 8,377,977 Robert More 41,013,686 3,705,719 8,377,977”
Earnings Releases
Tyra Biosciences, Inc. reported financial results for first quarter ended March 31, 2026.
“On May 13, 2026, Tyra Biosciences, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026.”
Adele M. Gulfo was appointed as Director at Tyra Biosciences, Inc..
“the Board appointed Adele M. Gulfo as a director of the Board, filling the Class I vacancy on the Board resulting from Ms. Kjellson’s resignation.”
Nina Kjellson resigned as Director at Tyra Biosciences, Inc..
“Nina Kjellson resigned from the Board and the Compensation Committee of the Board effective as of January 29, 2025”
Siddarth Subramony resigned as Director at Tyra Biosciences, Inc..
“On October 24, 2024, Siddarth Subramony, Ph.D. resigned from the Board of Directors (the Board) of Tyra Biosciences, Inc. (Tyra or the Company) and the Compensation Committee of the Board (the Compensation Committee) effective immediately.”
Earnings Releases
Tyra Biosciences, Inc. reported the quarter ended March 31, 2024 results: net income First quarter 2024 net loss was $18.2 million.
“On May 9, 2024, Tyra Biosciences, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024.”
S. Michael Rothenberg was appointed as Director at Tyra Biosciences, Inc..
“appointed Susan Moran, M.D., M.S.C.E. and S. Michael Rothenberg, M.D., Ph.D. as directors.”
Susan Moran was appointed as Director at Tyra Biosciences, Inc..
“appointed Susan Moran, M.D., M.S.C.E. and S. Michael Rothenberg, M.D., Ph.D. as directors.”
Isan Chen resigned as Director at Tyra Biosciences, Inc..
“Isan Chen, M.D. resigned from the Board and the Compensation Committee of the Board effective as of May 7, 2024.”
Earnings Releases
Tyra Biosciences, Inc. reported the fiscal year ended December 31, 2023 results: net income Full year 2023 net loss was $69.1 million.
“Full year 2023 net loss was $69.1 million compared to $55.3 million for the same period in 2022.”
Earnings Releases
Tyra Biosciences, Inc. reported the fourth quarter ended December 31, 2023 results: net income Fourth quarter 2023 net loss was $22.8 million.
“Fourth quarter 2023 net loss was $22.8 million compared to $12.9 million for the same period in 2022.”
Earnings Releases
Tyra Biosciences, Inc. reported the fourth quarter and full year ended December 31, 2023 results: net income net loss was $22.8 million.
“Tyra Biosciences, Inc. issued a press release announcing its financial results for the quarter and fiscal year ended December 31, 2023.”
Material Agreements
Tyra Biosciences, Inc. entered into Purchase Agreement with the purchasers named therein valued at approximately $200 million (effective 2024-02-01).
“On February 1, 2024, Tyra Biosciences, Inc. (the Company) entered into a securities purchase agreement (the Purchase Agreement) with the purchasers named therein (the Purchasers), for the private placement (the Private Placement) of (i) 9,286,023 shares (the Shares) of the Company’s common stock”
Earnings Releases
Tyra Biosciences, Inc. reported the quarter ended September 30, 2023 results: net income Third quarter 2023 net loss was $21.2 million.
“Third quarter 2023 net loss was $21.2 million compared to $12.5 million for the same period in 2022.”
Governance Changes
Tyra Biosciences, Inc.: Amended and restated bylaws to address universal proxy rules and enhance stockholder nomination procedures (effective 2023-10-26).
“On October 26, 2023, the Board of Directors (the Board) of Tyra Biosciences, Inc. (the Company) approved and adopted amended and restated bylaws (the Amended and Restated Bylaws), which became effective the same day.”
Earnings Releases
Tyra Biosciences, Inc. reported the quarter ended June 30, 2023 results: net income Second quarter 2023 net loss was $13.3 million.
“Second quarter 2023 net loss was $13.3 million compared to $15.1 million for the same period in 2022.”
Shareholder Votes
Tyra Biosciences, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-05-31 meeting.
“2. The ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The appointment was ratified by the votes indicated: For Against Abstain Broker Non-Votes 40,984,756 625 1,819 0”
Shareholder Votes
Tyra Biosciences, Inc. shareholders approved Election of three Class II directors to serve until the 2026 Annual Meeting of Stockholders at the 2023-05-31 meeting.
“1. The election of three directors to serve as Class II directors for a three-year term to expire at the 2026 Annual Meeting of Stockholders. The following three Class II directors were elected by the votes indicated: For Withheld Broker Non-Votes Isan Chen, M.D. 37,336,370 541,765 3,109,065 Gilla Kaplan, Ph.D. 37,581,968 296,167 3,109,065 Robert More 37,571,418 306,717 3,109,065”
Earnings Releases
Tyra Biosciences, Inc. reported the quarter ended March 31, 2023 results: net income $11.9 million.
“Tyra Biosciences, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2023.”
Earnings Releases
Tyra Biosciences, Inc. reported financial results for the quarter and fiscal year ended December 31, 2022.
“On March 22, 2023, Tyra Biosciences, Inc. issued a press release announcing its financial results for the quarter and fiscal year ended December 31, 2022.”
Earnings Releases
Tyra Biosciences, Inc. reported the quarter ended September 30, 2022 results: net income Third quarter 2022 net loss was $12.5 million.
“On November 3, 2022, Tyra Biosciences, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2022.”
Alan Fuhrman was appointed as Chief Financial Officer at Tyra Biosciences, Inc..
“On November 1, 2022, the Board of Directors of the Company (the “Board”) appointed Alan Fuhrman to replace Ms. van den Boom as the Company’s Chief Financial Officer, effective January 1, 2023.”
Esther van den Boom departed as Chief Financial Officer at Tyra Biosciences, Inc..
“On October 28, 2022, Esther van den Boom, the Chief Financial Officer of Tyra Biosciences, Inc. (the “Company”), informed the Company of her intent to resign as the Company’s Chief Financial Officer, effective December 31, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.